175 related articles for article (PubMed ID: 17069550)
1. A prospective, open-label trial of galantamine in autistic disorder.
Nicolson R; Craven-Thuss B; Smith J
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):621-9. PubMed ID: 17069550
[TBL] [Abstract][Full Text] [Related]
2. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
[TBL] [Abstract][Full Text] [Related]
3. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial.
Ghaleiha A; Ghyasvand M; Mohammadi MR; Farokhnia M; Yadegari N; Tabrizi M; Hajiaghaee R; Yekehtaz H; Akhondzadeh S
J Psychopharmacol; 2014 Jul; 28(7):677-85. PubMed ID: 24132248
[TBL] [Abstract][Full Text] [Related]
4. Clonidine treatment of hyperactive and impulsive children with autistic disorder.
Jaselskis CA; Cook EH; Fletcher KE; Leventhal BL
J Clin Psychopharmacol; 1992 Oct; 12(5):322-7. PubMed ID: 1479049
[TBL] [Abstract][Full Text] [Related]
5. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.
Marcus RN; Owen R; Kamen L; Manos G; McQuade RD; Carson WH; Aman MG
J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1110-1119. PubMed ID: 19797985
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.
King BH; Wright DM; Handen BL; Sikich L; Zimmerman AW; McMahon W; Cantwell E; Davanzo PA; Dourish CT; Dykens EM; Hooper SR; Jaselskis CA; Leventhal BL; Levitt J; Lord C; Lubetsky MJ; Myers SM; Ozonoff S; Shah BG; Snape M; Shernoff EW; Williamson K; Cook EH
J Am Acad Child Adolesc Psychiatry; 2001 Jun; 40(6):658-65. PubMed ID: 11392343
[TBL] [Abstract][Full Text] [Related]
7. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.
Research Units on Pediatric Psychopharmacology Autism Network
Am J Psychiatry; 2005 Jul; 162(7):1361-9. PubMed ID: 15994720
[TBL] [Abstract][Full Text] [Related]
8. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
Wake R; Miyaoka T; Inagaki T; Furuya M; Ieda M; Liaury K; Kishi K; Horiguchi J
J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
[TBL] [Abstract][Full Text] [Related]
9. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.
Wasserman S; Iyengar R; Chaplin WF; Watner D; Waldoks SE; Anagnostou E; Soorya L; Hollander E
Int Clin Psychopharmacol; 2006 Nov; 21(6):363-7. PubMed ID: 17012983
[TBL] [Abstract][Full Text] [Related]
10. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Research Units on Pediatric Psychopharmacology Autism Network
Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
[TBL] [Abstract][Full Text] [Related]
11. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study.
Cubo E; Fernández Jaén A; Moreno C; Anaya B; González M; Kompoliti K
Clin Ther; 2008 Jan; 30(1):182-9. PubMed ID: 18343255
[TBL] [Abstract][Full Text] [Related]
12. Guanfacine in children with autism and/or intellectual disabilities.
Handen BL; Sahl R; Hardan AY
J Dev Behav Pediatr; 2008 Aug; 29(4):303-8. PubMed ID: 18552703
[TBL] [Abstract][Full Text] [Related]
13. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.
Chez MG; Aimonovitch M; Buchanan T; Mrazek S; Tremb RJ
J Child Neurol; 2004 Mar; 19(3):165-9. PubMed ID: 15119476
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
Troost PW; Steenhuis MP; Tuynman-Qua HG; Kalverdijk LJ; Buitelaar JK; Minderaa RB; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):611-9. PubMed ID: 17069549
[TBL] [Abstract][Full Text] [Related]
15. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.
Valicenti-McDermott MR; Demb H
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):549-60. PubMed ID: 17069544
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
[TBL] [Abstract][Full Text] [Related]
17. Risperidone monotherapy in preschool children with pervasive developmental disorders.
Masi G; Cosenza A; Mucci M; De Vito G
J Child Neurol; 2001 Jun; 16(6):395-400. PubMed ID: 11417603
[TBL] [Abstract][Full Text] [Related]
18. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study.
Biederman J; Mick E; Faraone S; Hammerness P; Surman C; Harpold T; Dougherty M; Aleardi M; Spencer T
J Clin Psychopharmacol; 2006 Apr; 26(2):163-6. PubMed ID: 16633145
[TBL] [Abstract][Full Text] [Related]
19. Galantamine in the treatment of adult autism: a report of three clinical cases.
Hertzman M
Int J Psychiatry Med; 2003; 33(4):395-8. PubMed ID: 15152789
[TBL] [Abstract][Full Text] [Related]
20. An Open-label Trial of Risperidone and Fluoxetine in Children with Autistic Disorder.
Desousa A
Indian J Psychol Med; 2010 Jan; 32(1):17-21. PubMed ID: 21799554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
